Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress

Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA
                            Symposium and Congress

PR Newswire

SEATTLE, April 19, 2013

SEATTLE, April 19, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER)
today announced that it will present additional data from recent clinical
trials evaluating its ophthalmology product, OMS302, at the Annual American
Society of Cataract and Refractive Surgery and American Society of Ophthalmic
Administrators Symposium and Congress taking place in San Francisco April
19-23. The podium presentation, "Effect of an Anti-inflammatory-Mydriatic
Agent on the Incidence of Intraoperative Miosis During IOL Replacement
Surgery," summarizes key analyses of Phase 2 and Phase 3 clinical data
assessing the ability of OMS302 to reduce the incidence of miosis (pupil
constriction) during intraoperative lens replacement surgery. These analyses
will be included in both the US and European marketing applications for
OMS302. Steve Whitaker, M.D., Omeros' vice president of clinical development
and chief medical officer, will present the data at 3:27 p.m. PDT on April 21
in the Intraocular Surgery/Medications Session.

About Omeros' OMS302 Program
OMS302 is Omeros' product being developed for use during intraocular lens
replacement (ILR), including cataract surgery and refractive lens exchange.
OMS302 is a proprietary combination of the mydriatic (pupil dilating) agent
phenylephrine and the anti-inflammatory agent ketorolac. Omeros recently
completed its successful OMS302 Phase 3 clinical program and expects to submit
a New Drug Application to the U.S. Food and Drug Administration this quarter
and a Marketing Authorization Application to the European Medicines Agency in

ILR involves replacement of the original lens of the eye with an artificial
intraocular lens. These procedures are typically performed to replace a lens
opacified by a cataract or to correct a refractive error of the lens (i.e.,
refractive lens exchange). OMS302 is added to standard irrigation solution
used in ILR and delivered within the eye to maintain intraoperative mydriasis
(pupil dilation), to prevent surgically induced miosis (pupil constriction),
and to reduce postoperative pain and irritation. Maintenance of mydriasis is
critical to the safety and surgical ease of the procedure. Intraoperative
pupil constriction increases the risk of injury to intraocular structures and
can substantially prolong surgical time.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing products targeting inflammation, coagulopathies
and disorders of the central nervous system. The Company's most clinically
advanced product candidates, OMS302 for lens replacement surgery and OMS103HP
for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform
designed to improve clinical outcomes of patients undergoing a wide range of
surgical and medical procedures. Omeros has five clinical development
programs. Omeros may also have the near-term capability, through its GPCR
program, to add a large number of new drug targets and their corresponding
compounds to the market. Behind its clinical candidates and GPCR platform,
Omeros is building a diverse pipeline of protein and small-molecule
preclinical programs targeting inflammation, coagulopathies and central
nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the
Private Securities Litigation Reform Act of 1995, which are subject to the
"safe harbor" created by those sections. These statements include, but are not
limited to, Omeros' expectations regarding when it will submit marketing
applications for OMS302; and that Omeros may have capability, through its GPCR
program, to add a large number of new drug targets and their corresponding
compounds to the market. Forward-looking statements are based on management's
beliefs and assumptions and on information available to management only as of
the date of this press release. Omeros' actual results could differ materially
from those anticipated in these forward-looking statements for many reasons,
including, without limitation, the risks, uncertainties and other factors
described under the heading "Risk Factors" in the Company's Annual Report on
Form 10-K filed with the Securities and Exchange Commission on March 18, 2013.
Given these risks, uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and the Company assumes no
obligation to update these forward-looking statements publicly, even if new
information becomes available in the future.

SOURCE Omeros Corporation

Contact: Jennifer Cook Williams, Cook Williams Communications, Inc., Investor
and Media Relations, +1-360-668-3701,
Press spacebar to pause and continue. Press esc to stop.